Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis

Table 1

Characteristics of included randomized controlled trials comparing specific drugs for treatment of CTEPH.

Author	Year	Trial acronym	Duration	Therapy (sample size)	Age (year)	Female	Male	Dose	Multicenter	Blind
Kramm	2005	—	Hospital discharge	Iloprost (n = 11); Placebo (n = 11)	54 ± 17; 56 ± 13	36%; 36%	64%; 64%	25 ug	Single	Double
Jais X	2008	BENEFIT	16 weeks	Bosentan (n = 77); Placebo (n = 80)	63 ± 12.9; 63.1 ± 10.3	71%; 59%	29%; 41%	125 mg bid	Multi	Double
Suntharalingam	2008	—	12 weeks	Sildenafil (n = 9); Placebo (n = 10)	49.9 ± 13.1; 60.0 ± 14.4	78%; 30%	22%; 70%	40 mg tid	Single	Double
Reesink	2010	—	16 weeks	Bosentan (n = 14); Placebo (n = 12)	67 ± 8; 64 ± 10	71%; 66%	29%; 34%	125 mg bid	Single	Single
Ghofrani	2013	CHEST-1	16 weeks	Riociguat (n = 173); Placebo (n = 88)	59 ± 14; 59 ± 13	68%; 61%	32%; 39%	2.5 mg tid	Multi	Double
Ghofrani	2018	MERIT-1	24 weeks	Macitentan (n = 40); Placebo (n = 40)	58.2 ± 14; 56.9 ± 13.9	65%; 63%	35%; 38%	10 mg qd	Multi	Double
Escribano-Subias P	2019	AMBER 1	16 weeks	Ambrisentan (n = 17); Placebo; (n = 16)	61.2 ± 13.4; 59.8 ± 9	47%; 63%	53%; 37%	5 mg qd	Multi	Double
Sadushi-Kolici R	2019	CTREPH	24 weeks	Treprostinil (n = 53); Low-dose Trepro-stinil (n = 52)	68 ± 11.2; 61 ± 14.6	36%; 58%	64%; 42%	30 ng/kg/min; 3 ng/kg/min	Multi	Double